Market Newsdesk

• Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeled
• Company plans to proceed directly to a streamlined final analysis for the primary endpoint, PFS, while strengthening power for the secondary endpoint, OS, to enhance the commercial product profile
• SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027, followed by BLA submission in 2027
• Anzu-cel PRAME Cell Therapy: Updated Phase 1b data at ASCO 2026 continued to show durable anti-tumor activity in metastatic melanoma, with 56% cORR, 14.6 months mDOR, 6.1 months mPFS, 16.2 months mOS and a 2-year OS rate of 46%, as well as predictable and manageable tolerability
• IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ASCO 2026 demonstrated clinical activity in hard-to-treat gynecologic cancers with a 63% ORR and 50% cORR; updated data across multiple PRAME-positive solid tumors are planned for presentation at the ESMO Congress 2026
• IMA402 PRAME Bispecific: Phase 1b data at recommended Phase 2 dose (RP2D) range across multiple cancers planned for presentation at the ESMO Congress 2026
• IMA402 PRAME / IMA401 MAGEA4/8 Bispecific Combination: Combination cohort in sqNSCLC enrolling patients with first data expected in 2027
• Cash and cash equivalents as well as other financial assets of $448.2 million¹ (€393.4 million) as of June 30, 2026; cash reach projected into 2028

Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended June 30, 2026.

“The Phase 3 SUPRAME trial continues to enroll patients on schedule across sites in North America and Europe. In parallel, the data from the Phase 1b anzu-cel study continue to mature. We are now observing that aggregate progression and death events in the SUPRAME trial are occurring more slowly than originally modeled. Based on these results and FDA feedback, we plan to proceed directly to a streamlined final analysis, while maintaining robust statistical power for the primary PFS endpoint,” said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. “We believe this approach provides the most efficient path to generating definitive data for regulatory approval and look forward to reporting topline results in the first half of 2027. We continue to build the foundation for the commercial launch to bring anzu-cel to patients who urgently need new treatment options, while advancing the PRAME franchise across our pipeline.”

Second Quarter 2026 and Subsequent Company Progress

PRAME Franchise


– Cell Therapy

Anzu-cel (IMA203) PRAME Cell Therapy – First Market Entry in Advanced Melanoma

Anzu-cel (anzutresgene autoleucel), previously called IMA203, is Immatics’ lead PRAME cell therapy and is expected to be the Company’s first PRAME therapy to enter the market in advanced melanoma. The current addressable patient population for anzu-cel’s first target indications, second-line or later (2L) advanced cutaneous melanoma, as well as metastatic uveal melanoma includes ~9,000 patients

²

.

Phase 3 trial, SUPRAME, for anzu-cel

(IMA203)

in previously treated, advanced melanoma

• Immatics’ global, randomized, controlled, multi-center Phase 3 clinical trial, SUPRAME, is currently ongoing to evaluate the efficacy, safety and tolerability of anzu-cel PRAME cell therapy as monotherapy vs. investigator’s choice in patients with unresectable or metastatic melanoma who have received prior treatment with a PD-1 immune checkpoint inhibitor. Anzu-cel received FDA Orphan Drug Designation and FDA RMAT designation, which includes all benefits of FDA Breakthrough Therapy Designation.
• SUPRAME is designed to be an adequate and well-controlled clinical trial to generate the data supporting full regulatory approval of anzu-cel.
• The primary endpoint for SUPRAME is blinded independent central review (“BICR”)-assessed (RECIST v1.1) progression-free survival (PFS). Key secondary endpoints include overall survival (OS), objective response rate (ORR), safety and patient-reported outcomes measuring quality of life.
• Enrollment in SUPRAME, currently ongoing in North America and Europe, remains on track to complete required randomizations by year-end to support final analysis for the primary endpoint.
• The aggregate number of PFS events (progressive disease or death) in the SUPRAME trial is occurring more slowly than originally modeled.
• As a result, Immatics intends to replace the previously planned interim and final PFS analyses with a single streamlined final analysis, now based on a lower prespecified number of PFS events while maintaining a robust power of 90% for the primary endpoint.
• At the same time, Immatics intends to increase the statistical power for the secondary endpoint of OS by enrolling approximately 90 additional patients, bringing the total trial size to approximately 450 patients. This aims to further strengthen the commercial product profile of anzu-cel. The increased number of events needed for the final OS analysis has no impact on the timing of the final PFS analysis.
• These planned protocol amendments are based on feedback from the FDA following recent interaction with the agency, with whom Immatics continues to engage.
• The Company expects to disclose topline data from the final PFS analysis in the first half of 2027, followed by a BLA submission in 2027.
• The Company continues to build the commercial infrastructure for the anticipated launch of anzu-cel after obtaining BLA approval.

Phase 1/2 trial for anzu-cel

(IMA203)

in previously treated, metastatic melanoma

• Updated Phase 1b clinical data presented at the 2026 ASCO Annual Meeting showed durable anti-tumor activity at longer follow-up in metastatic melanoma, including 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS. The OS rate was 70% at 12 months and 46% at 24 months. Anzu-cel maintained a predictable and manageable tolerability profile. Explorative analyses focusing on predictors of durable response have been accepted for presentation at the ESMO Congress 2026.

Phase 2 cohort for anzu-cel (IMA203) PRAME cell therapy in patients with metastatic uveal melanoma

• A Phase 2 cohort to treat approximately 30 additional patients with metastatic uveal melanoma is ongoing and being conducted at select centers in the U.S. and Germany with expertise in uveal melanoma.
• Data from the ongoing single-arm Phase 1b trial as well as the Phase 2 cohort in metastatic uveal melanoma are intended to support a potential label expansion for anzu-cel following expected initial approval in unresectable or metastatic melanoma.

IMA203CD8 PRAME Cell Therapy – Expansion to All Advanced PRAME Cancers

IMA203CD8 is the Company’s PRAME cell therapy product candidate being developed with the goal of expanding into all advanced PRAME cancers. Given its enhanced pharmacology profile, the Company intends to pursue the clinical development of this product candidate with a tumor-agnostic approach, including gynecologic cancers (ovarian and uterine).

• Updated Phase 1 data in hard-to-treat gynecologic cancers presented at the 2026 ASCO Annual Meeting demonstrated anti-tumor activity at clinically relevant doses, including 63% ORR and 50% confirmed ORR, four complete responses and the longest ongoing response at 12 months. Additional data in synovial sarcoma showed a 67% ORR and 64% confirmed ORR, including one complete response and ongoing responses for up to approximately three years. IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations.
• The clinical activity observed to date across tumor types (ovarian carcinoma, uterine cancer, melanoma, synovial sarcoma) with distinct biology and differing levels of PRAME expression supports the broad applicability of IMA203CD8 across solid tumors.
• The Company completed Phase 1a dose escalation as planned in mid-2026.
• Updated Phase 1 data from IMA203CD8 across multiple PRAME-positive solid tumors will be presented at ESMO Congress 2026.
• In addition to its broad expression across more than 50 adult cancer types, PRAME is highly prevalent in multiple pediatric cancers. A case report published in the New England Journal of Medicine³ highlights the therapeutic potential of PRAME TCR T-cell therapy in pediatric patients with solid tumors. Immatics intends to support further clinical evaluation in this population by manufacturing and supplying IMA203CD8 PRAME TCR T-cell therapy for the planned investigator-initiated Phase 1/2 PRAMEtime trial at Hopp Children’s Cancer Center Heidelberg (KiTZ), Germany.

PRAME Franchise – Bispecifics

IMA402 PRAME Bispecific – Expansion to Earlier-Line PRAME Cancers

To expand the PRAME opportunity to earlier-line PRAME cancers, the Company is developing its off-the-shelf, next-generation, half-life extended TCR bispecific, IMA402, as a monotherapy or in combination with standard of care, with a focus on melanoma and gynecologic cancers. In addition, Immatics is exploring the combination of IMA402 PRAME bispecific with IMA401 MAGEA4/8 bispecific in squamous non-small cell lung cancer (sqNSCLC)
and potentially other solid tumor indications.

• IMA402 PRAME bispecific showed clinical proof-of-concept during the Phase 1a dose escalation trial in heavily pre-treated patients with solid tumors, including melanoma and ovarian cancer.
• As part of its strategy to maximize IMA402 opportunity, the Company opened additional Phase 1b cohorts in mid-2026 across both earlier and later treatment lines and is currently evaluating IMA402 as monotherapy and in combination with immune checkpoint inhibitors.
• Phase 1b data from IMA402 at the RP2D range across multiple cancers will be presented at ESMO Congress 2026.
• Based on the initial promising activity of IMA401 in head and neck cancer and sqNSCLC presented at ASCO 2026 and published simultaneously in Nature Medicine, Immatics has initiated a Phase 1b cohort evaluating IMA402 targeting PRAME in combination with IMA401 targeting MAGEA4/8 in sqNSCLC at multiple clinical trial sites. First data from the IMA402/IMA401 combination cohort are expected in 2027.

Corporate Development:

• In collaboration, Moderna and Immatics discovered a cancer antigen therapeutic candidate (mRNA-4200) under the Database Program, incorporating targets identified using Immatics’ XPRESIDENT® target discovery and validation platform and its bioinformatics and AI platform XCUBE®. The first patient in the clinical trial sponsored by Moderna was dosed in July, 2026, marking a key clinical milestone and triggering a milestone payment to Immatics.
• Immatics’ General Counsel and Corporate Secretary, Edward Sturchio, has decided to transition out of the Company to pursue other opportunities after more than six years with Immatics. He played a key role in supporting the Company through its transition to a public company and pre-commercial growth stage.
• Effective July 20, 2026, Jim Pepin has been appointed as General Counsel and Corporate Secretary and joined Immatics’ Executive Team. Mr. Pepin brings more than 20 years of legal leadership experience across life sciences and consumer health industries, with expertise spanning public-company governance, compliance, transactions and intellectual property strategy. Most recently, he served as General Counsel of Legend Biotech, a global commercial-stage cell therapy company, and previously served as General Counsel and Corporate Secretary at Aimmune Therapeutics and Nestlé Health Science USA.

Second Quarter 2026 Financial Results

Cash Position: Cash and cash equivalents, as well as other financial assets, total $448.2 million¹ (€393.4 million) as of June 30, 2026, compared to $534.7 million¹ (€469.3 million) as of December 31, 2025. The decrease is the result of ongoing research and development activities, partially offset by the net proceeds of an at-the-market offering of $24.2 million¹ (€21.2 million) as well as changes in net working capital and foreign exchange rate differences.

Revenue: Total revenue, consisting of revenue from collaboration agreements, was $10.4 million¹ (€9.1 million) for the three months ended June 30, 2026, compared to $5.4 million¹ (€4.7 million) for the three months ended June 30, 2025. The increase is mainly due to a higher level of activity and proportion of costs incurred relative to the overall plan of collaboration activities within the quarter.

Research and Development Expenses: R&D expenses were $71.1 million¹ (€62.4 million) for the three months ended June 30, 2026, compared to $51.4 million¹ (€45.1 million) for the three months ended June 30, 2025. The increase mainly resulted from costs associated with advancing the product candidates in clinical trials, particularly the SUPRAME trial.

General and Administrative Expenses: G&A expenses were $15.8 million¹ (€13.9 million) for the three months ended June 30, 2026, compared to $14.6 million¹ (€12.8 million) for the three months ended June 30, 2025. The increase mainly results from activities in preparation for commercialization.

Net Profit and Loss: Net loss was $71.2 million¹ (€62.5 million) for the three months ended June 30, 2026, compared to a net loss of $80.1million¹ (€70.3 million) for the three months ended June 30, 2025. The decrease is mainly driven by unrealized non-cash foreign exchange rate losses during the three months ended June 30, 2025, and to a lesser extent by higher collaboration revenue, partially offset by higher costs associated with the SUPRAME trial in the three months ended June 30, 2026.

Full financial statements can be found in our Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on August 18, 2026, and published on the SEC website under www.sec.gov.

Upcoming Investor Conferences

• Jefferies Global Healthcare Conference, London, United Kingdom – November 16 – 19, 2026

To see the full list of events and presentations, visit: https://investors.immatics.com/events-presentations.

About PRAME
PRAME is a tumor-associated target expressed in more than 50 cancers. Immatics’ PRAME franchise includes multiple product candidates, therapeutic modalities, indications and combination approaches: anzu-cel (anzutresgene autoleucel; IMA203) and IMA203CD8, both PRAME-directed cell therapies, and IMA402, a PRAME-directed bispecific. Combination approaches include IMA402 with immune checkpoint inhibitors, IMA402 with the MAGEA4/8-directed bispecific IMA401, and anzu-cel in combination with Moderna’s PRAME mRNA therapy designed to enhance the cell therapy response.

About Immatics

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing and outcomes of IND, CTA or BLA filings or commercial launches, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.

For more information, please contact:

Media         
Trophic Communications        
Phone: +49 151 74416179         
[email protected]

Immatics N.V.        
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
[email protected]

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Loss of Immatics N.V.

		Three months ended June 30,					Six months ended June 30,
		2026		2025			2026		2025
		(Euros in thousands, except per share data)					(Euros in thousands, except per share data)
Revenue from collaboration agreements		9,144		4,737			16,756		23,318
Research and development expenses		(62,411)		(45,106)			(121,597)		(87,014)
General and administrative expenses		(13,937)		(12,780)			(28,450)		(24,847)
Other income		—		22			24		41
Operating result		(67,204)		(53,127)			(133,267)		(88,502)
Change in fair value of liabilities for warrants		—		133			—		1,730
Other financial income		4,802		4,421			13,341		10,685
Other financial expenses		(364)		(22,776)			(602)		(36,113)
Financial result		4,438		(18,222)			12,739		(23,698)
Loss before taxes		(62,766)		(71,349)			(120,528)		(112,200)
Taxes on income		274		1,001			222		1,996
Net loss		(62,492)		(70,348)			(120,306)		(110,204)
Net loss per share:
Basic		(0.46)		(0.58)			(0.89)		(0.91)
Diluted		(0.46)		(0.58)			(0.89)		(0.91)

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.

		Three months ended June 30,					Six months ended June 30,
		2026		2025			2026		2025
		(Euros in thousands)					(Euros in thousands)
Net loss		(62,492)		(70,348)			(120,306)		(110,204)
Other comprehensive income/(loss)
Items that may be reclassified subsequently to profit or loss
Currency translation differences from foreign operations		1,191		(5,833)			3,066		(8,544)
Total comprehensive loss for the period		(61,301)		(76,181)			(117,240)		(118,748)

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Financial Position of Immatics N.V.

		As of
		June 30, 2026		December 31, 2025
		(Euros in thousands)
Assets
Current assets
Cash and cash equivalents		232,459		345,918
Other financial assets		160,891		123,419
Accounts receivables		5,629		6,099
Other current assets		30,213		28,572
Total current assets		429,192		504,008
Non-current assets
Property, plant and equipment		39,981		42,111
Intangible assets		1,562		1,582
Right-of-use assets		11,717		12,786
Other non-current assets		3,283		1,850
Total non-current assets		56,543		58,329
Total assets		485,735		562,337
Liabilities and shareholders’ equity
Current liabilities
Provisions		5,901		—
Accounts payables		33,155		18,832
Deferred revenue		9,567		15,816
Lease liabilities		2,666		2,757
Other current liabilities		5,664		5,607
Total current liabilities		56,953		43,012
Non-current liabilities
Deferred revenue		13,632		18,541
Lease liabilities		11,940		12,878
Deferred tax liabilities		3,585		3,807
Total non-current liabilities		29,157		35,226
Shareholders’ equity
Share capital		1,367		1,341
Share premium		1,310,078		1,277,338
Accumulated deficit		(906,294)		(785,988)
Other reserves		(5,526)		(8,592)
Total shareholders’ equity		399,625		484,099
Total liabilities and shareholders’ equity		485,735		562,337

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Cash Flows of Immatics N.V.

		Six months ended June 30,
		2026		2025
		(Euros in thousands)
Cash flows from operating activities
Net loss		(120,306)		(110,204)
Taxes on income		(222)		(1,996)
Loss before tax		(120,528)		(112,200)
Adjustments for:
Interest income		(6,867)		(9,719)
Depreciation and amortization		5,777		6,166
Interest expenses		415		493
Equity-settled share-based payment		10,977		8,471
Net foreign exchange differences and expected credit losses		(6,833)		34,241
Change in fair value of liabilities for warrants		—		(1,730)
Loss from disposal of fixed assets		48		40
Changes in:
Decrease in accounts receivables		610		3,894
Increase in other assets		(1,260)		(277)
Increase/(decrease) in deferred revenue, accounts payables and other liabilities		9,876		(15,534)
Interest received		7,022		18,012
Interest paid		(415)		(493)
Income tax paid		(1,326)		(5,445)
Income tax refunded		—		820
Net cash used in operating activities		(102,504)		(73,261)
Cash flows from investing activities
Payments for property, plant and equipment		(1,634)		(4,503)
Payments for intangible assets		—		(190)
Proceeds from disposal of property, plant and equipment		27		47
Payments for investments classified in other financial assets		(140,165)		(280,651)
Proceeds from maturity of investments classified in other financial assets		105,535		396,353
Net cash provided by/(used in) investing activities		(36,237)		111,056
Cash flows from financing activities
Proceeds from issuance of shares to equity holders		22,330		9
Transaction costs deducted from equity		(542)		—
Payments of lease liabilities		(1,483)		(1,473)
Net cash provided by/(used in) financing activities		20,305		(1,464)
Net increase/(decrease) in cash and cash equivalents		(118,436)		36,331
Cash and cash equivalents at the beginning of the period		345,918		236,748
Effects of exchange rate changes and expected credit losses on cash and cash equivalents		4,977		(16,444)
Cash and cash equivalents at the end of the period		232,459		256,635

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Changes in Shareholders’ Equity of Immatics N.V. 

(Euros in thousands)		Share capital		Share premium		Accumulated deficit		Other reserves		Total share- holders’ equity
Balance as of January 1, 2025		1,216		1,162,136		(589,541)		1,031		574,842
Other comprehensive loss		—		—		—		(8,544)		(8,544)
Net loss		—		—		(110,204)		—		(110,204)
Comprehensive loss for the period		—		—		(110,204)		(8,544)		(118,748)
Equity-settled share-based compensation		—		8,471		—		—		8,471
Share options exercised		—		9		—		—		9
Balance as of June 30, 2025		1,216		1,170,616		(699,745)		(7,513)		464,574
Balance as of January 1, 2026		1,341		1,277,338		(785,988)		(8,592)		484,099
Other comprehensive income		—		—		—		3,066		3,066
Net loss		—		—		(120,306)		—		(120,306)
Comprehensive income/(loss) for the period		—		—		(120,306)		3,066		(117,240)
Equity-settled share-based compensation		—		10,977		—		—		10,977
Share options exercised		1		636		—		—		637
Issue of share capital – net of transaction costs		25		21,127		—		—		21,152
Balance as of June 30, 2026		1,367		1,310,078		(906,294)		(5,526)		399,625

        

---

¹ All amounts converted using the exchange rate published by the European Central Bank in effect as of June 30, 2026 (1 EUR = 1.1394 USD).
² Refers to PRAME+/HLA-A*02:01+ patients per year in the U.S. and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast.
³ Mair K, et al. N Engl J Med. 2026;395:721-724

Attachment

• PDF Version

Strategy update positions WGMI to capture the build-out of the energy and compute backbone behind bitcoin and artificial intelligence, anchored in the listed bitcoin miners that already operate it.

JERSEY, Channel Islands — August 18, 2026 — CoinShares PLC (Nasdaq: CSHR) (“CoinShares” or the “Company”), a leading global asset manager specializing in digital assets, today announced that US-listed mining ETF, WGMI, issued by CoinShares ETF Trust, has been renamed the CoinShares Bitcoin Mining and Digital Power ETF (NASDAQ: WGMI) (the “Fund”), formerly the CoinShares Bitcoin Miners ETF. The ticker is unchanged.

The strategy update broadens the Fund’s investment universe to reflect a structural shift underway across the listed mining sector: bitcoin miners are increasingly the operators of the gigawatt-scale, grid-connected, low-latency compute infrastructure that AI and high-performance computing depend on.

WGMI will now invest at least 80% of its net assets in Bitcoin Mining and Digital Power Companies, a category the prospectus now defines to include companies materially involved in bitcoin mining, hyperscale data centers, semiconductors and components for AI and data-center workloads, power generation and energy infrastructure essential to data centers, and high-performance and quantum computing supporting AI. The Fund previously focused solely on bitcoin mining companies that derive 50% of their revenue from bitcoin mining or provide the hardware and software for bitcoin mining. The Fund will not directly invest in bitcoin, nor indirectly through derivatives or through investments in funds or trusts that hold bitcoin.

Why now

Three forces are converging on the same set of companies:

• Post-halving mining economics. The April 2024 halving cut block subsidies in half; the next halving in 2028 will halve them again. Publicly listed bitcoin miners have responded by monetizing existing power capacity, infrastructure, and ASIC-trained operations teams to host AI and HPC workloads alongside, and in some cases instead of, mining.
• AI’s energy and siting bottleneck. Hyperscalers face multi-year lead times for transformers, substations, and grid interconnections. Listed miners already hold permitted, energized sites at a scale measured in gigawatts, a footprint the rest of the market is racing to build.
• A clarifying US regulatory backdrop. US digital-asset policy has converged decisively over the past twelve months: the CLARITY Act, which delineates SEC/CFTC jurisdiction and defines most blockchain-native assets as digital commodities, passed the US House in July 2025. The Senate version of the legislation is expected to be voted on by mid-August 2026. Also, in March 2026, the SEC and CFTC issued a joint token taxonomy that formally referenced bitcoin as a digital commodity. Together, these regulatory developments materially reduce ambiguity in the United States around bitcoin and the listed companies whose business models are built around it.

WGMI’s strategy update is designed to keep investors aligned with this convergence rather than constrained by a definition of “miner” that has narrowed as the industry has diversified.

Jean-Marie Mognetti, President and CEO of CoinShares commented:

“The line between a bitcoin miner and a digital infrastructure operator has been disappearing for two years, and the market has been waiting for someone to say so out loud. Listed miners have spent a decade building exactly what AI now needs at scale: energized sites, custom power agreements, immersion cooling, and engineering teams who know how to run dense compute 24/7. Renaming WGMI as the Bitcoin Mining and Digital Power ETF is not a pivot away from mining. It is a recognition that many of the most strategic mining companies in the world are now also among the most strategic compute infrastructure operators.”

Calvin Tintle, Head of U.S Sales of CoinShares Asset Management (US) added:

“Advisors have been asking us for a single ticker that captures both the bitcoin mining narrative and the AI compute build-out without direct token exposure. WGMI is designed to give them that exposure in one wrapper. We are seeing demand from thematic, infrastructure, and crypto-native allocators who, until today, had to combine multiple products to express what is fundamentally one thematic allocation.”

What stays the same

• Ticker: WGMI, listed on Nasdaq.
• Adviser: Actively managed by CoinShares Asset Management (US) LLC, with Vident Asset Management as sub-adviser.
• Portfolio managers: Bill Cannon, Rafael Zayas, CFA, and Austin Wen, CFA, continue in their roles.
• Structure: Daily liquidity, transparent ETF wrapper, US-domiciled.

On August 11 2026, WGMI changed the investment strategy of the fund. Any performance prior to this change may have been affected by this change.

About CoinShares

CoinShares PLC (“CoinShares”) is a leading global asset manager specialising in digital assets, that delivers a broad range of financial services across investment management, trading and securities to a wide array of clients that includes corporations, financial institutions and individuals. Focusing on crypto since 2013, the firm is headquartered in Jersey, with offices in France, Sweden, Switzerland, the UK and the United States. CoinShares’ affiliated entities are regulated in Jersey by the Jersey Financial Services Commission, in France by the Autorité des marchés financiers, and in the US by the Securities and Exchange Commission, National Futures Association and Financial Industry Regulatory Authority. CoinShares PLC is publicly listed on the Nasdaq under the ticker CSHR.

Additional information about WGMI can be found by visiting:  https://coinshares.com/us/etf/wgmi/
For more information on CoinShares, please visit: https://coinshares.com

Company | +44 (0)1534 513 100 | [email protected]
Investor Relations | +44 (0)1534 513 100 | [email protected]

Press Contact

CoinShares
Benoît Pellevoizin
[email protected]

M Group Strategic Communications
Peter Padovano
[email protected]

Investing involves risk, including possible loss of principal. Before investing, carefully consider the Fund’s investment objectives, risks, charges, and expenses, which are contained in the prospectus and summary prospectus available at


https://coinshares.com/us/etf/wgmi/


. WGMI may not be suitable for all investors. Diversification does not eliminate risk or guarantee against a loss. Investors should read the prospectus carefully before investing and carefully consider the risks outlined in the prospectus before investing in the Fund.

Risk of Reduced Returns due to Fees. Shares of Exchange Traded Funds are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Applicable brokerage fees and commissions will likely reduce returns.

Evolving Asset Risk. This is a new ETF with limited operating history. Digital assets are a new technological innovation with a limited history. There is no assurance that usage of digital assets will continue to grow. A contraction in use of digital assets may result in increased volatility or a reduction in the price of the Exchange Traded Products, which could adversely impact the value of the Fund. The Fund provides exposure to companies involved in bitcoin mining operations and doesn’t invest directly in bitcoin. It invests at least 80% of its net assets in securities of companies that derive at least 50% of their revenue or profits from bitcoin mining operations or from providing specialized chips, hardware and software or other services to companies engaged in bitcoin mining.

Bitcoin Investing Risk. The Fund is indirectly exposed to the risks of investing in bitcoin through its investments in the portfolio companies.

AI Companies Risk: AI Companies Risk. The Fund invests in companies that are involved in various aspects of AI. AI companies are significantly affected by changes in business cycles, world economic growth, technological progress, rapid obsolescence, and government regulation. AI companies may have limited product lines, markets, financial resources or personnel. Rapid change to technologies that affect a company’s products could have a material adverse effect on such company’s operating results.

Bitcoin is a new and highly speculative investment. Bitcoin is a new technological innovation with a limited history. There is no assurance that usage of bitcoin will continue to grow. A contraction in use of bitcoin may result in increased volatility or a reduction in the price of bitcoin, which could adversely impact the value of the Fund. The Bitcoin Network was launched in January 2009, platform trading in bitcoin began in 2010, and bitcoin futures trading began in 2017, each of which limits a potential shareholder’s ability to evaluate an investment in the Fund. The Fund’s investments are exposed to risks associated with the price of bitcoin, which is subject to numerous factors and risks, including but not limited to the available global supply of bitcoin and global demand for bitcoin. Please see the prospectus for additional disclosures relating to the risks associated with investing in WGMI.

Cryptocurrencies are subject to unique and substantial risks, including significant price volatility and lack of liquidity. The value of a cryptocurrency may decline significantly without warning, including to zero. Cryptocurrencies are largely unregulated and cryptocurrency-linked investments may be more susceptible to fraud and manipulation than more regulated investments.

If a fund’s ability to obtain exposure to cryptocurrency-linked investments consistent with their investment objectives is disrupted for any reason, including as a result of a lack of liquidity, volatility, or a disruption in the cryptocurrency or cryptocurrency futures market, or as a result of margin requirements, position limits, or other conditions, factors, or limitations of a particular fund, the fund may not be able to achieve its investment objective and may experience significant losses.

The Fund is distributed by ALPS Distributors, Inc.

As a global medical cannabis leader, Tilray Medical supports continued policy development that strengthens physician confidence, protects patient access and provides a clear, sustainable framework for medical cannabis in Germany.

The guidance issued by the KBV and GKV-Spitzenverband represents an important step forward by providing greater practical direction for the prescribing of standardized full-spectrum cannabis extracts. Tilray Medical welcomes this progress and encourages policymakers to build upon it with legislative clarity that provides physicians, patients, healthcare providers and payers with a consistent and durable framework for medical cannabis care.

DENSBORN, Germany, Aug. 18, 2026 (GLOBE NEWSWIRE) —  Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), considers the recent guidance issued by the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) on the prescription of medical cannabis in the form of standardized full-spectrum extracts a step in the right direction. Important legal and regulatory questions nevertheless remain unresolved under Germany’s revised framework for reimbursed medical cannabis prescribing. Durable legal certainty for physicians, patients, healthcare providers and payers will ultimately require legislative clarification.

Rajnish Ohri, President, International, Tilray Brands, said, “The guidance represents meaningful progress and provides valuable direction for healthcare professionals navigating medical cannabis prescribing. Continued legislative clarity will help strengthen confidence in the framework and support long-term stability for patients, physicians and healthcare providers.”

Practical Clarity from the KBV and GKV-Spitzenverband Guidance

The current interpretation issued by the KBV and the GKV-Spitzenverband provides important practical clarity for healthcare professionals and patients. It represents a constructive step toward safeguarding patient access to treatment and creating a more predictable prescribing framework.

Mr. Ohri, added, “Germany continues to set an important example for medical cannabis in Europe by advancing a thoughtful, science-based framework that puts patients and physicians at the center of care. Tilray Medical is committed to working with physicians, regulators and industry partners to help strengthen confidence in Germany’s medical cannabis system and ensure patients have access to the therapies that best meet their needs.”

Remaining Legal and Regulatory Questions

First, physicians require greater certainty regarding the appropriate use of cannabis-based therapies, including standardized full-spectrum extracts and other magistral preparations. Practical guidance and access to a broad range of pharmaceutical-quality cannabis medicines remain essential to ensuring that treatment decisions are driven by clinical need and patient outcomes. The principle that finished medicinal products should be trialed only within their approved indication, and that ineffective or poorly tolerated therapies should not be unnecessarily prolonged, supports sound medical practice and protects physician autonomy.

Second, continuity of care must remain a priority for patients already benefiting from cannabis-based treatment. Patients stabilized on standardized full-spectrum extracts or other magistral preparations should be protected from avoidable treatment disruptions. Regulatory certainty is necessary so that therapeutic decisions remain focused on individual patient needs. Administrative uncertainty should not determine the course of a treatment.

Third, as reimbursement rules continue to evolve, all stakeholders would benefit from greater predictability regarding treatment pathways and reimbursement eligibility. Patients, physicians, health insurers and healthcare providers need a stable statutory framework that supports responsible access and consistent implementation throughout the healthcare system.

The Case for Legislative Clarification

Tilray Medical supports a clear statutory framework that protects physicians’ freedom of therapy and safeguards continuity of care for existing patients. Such a framework would also provide greater predictability regarding reimbursement and treatment pathways. Codifying these principles in legislation would reduce implementation uncertainty and ensure sustainable patient access to appropriate therapies.

Mr. Ohri, continued, “The current guidance represents meaningful progress. Building on this progress through additional legislative clarity and codifying this interpretation in law would preserve physicians’ freedom of therapy and maintain a predictable reimbursement framework. It would also give patients, healthcare providers and health insurers the long-term planning reliability they need.”

Strengthening Physician Decision-Making

Tilray Medical believes physicians need practical guidance and access to a broad range of pharmaceutical-quality cannabis medicines. The clarification that finished medicinal products should be trialed only within their approved indication, and that ineffective or poorly tolerated treatments should not be prolonged, supports sound clinical judgment and helps avoid unnecessary disruption for patients already stable on standardized full-spectrum extracts or other magistral preparations.

Supporting a Responsible Transition for Patients

With reimbursement changes affecting cannabis flower, patients should have timely access to appropriate alternatives, including standardized full-spectrum extracts. Through its cultivation, manufacturing and distribution operations in Germany, supported by its global medical cannabis platform and quality standards, Tilray Medical is well positioned to support the market responsibly while helping ensure reliable access for patients and healthcare providers.

Supporting Germany Through a Reliable Medical Cannabis Platform

Tilray Medical supports continued collaboration among policymakers, physicians, regulators and industry leaders as Germany advances its medical cannabis system. With international scale, a broad product portfolio and deep operating experience, Tilray Medical is well positioned to help shape the next phase of responsible cannabis care in Germany and across Europe.

Tilray Medical’s presence in Germany reflects years of investment in a reliable, integrated medical cannabis platform. The Company holds a leading position in Germany’s medical cannabis oil market, with 45% market share, supported by cultivation and manufacturing capabilities in Germany and Portugal, including its Aphria RX facility and the ARX brand developed for German patients. Through CC Pharma, Tilray also reaches approximately 16,000 pharmacies and major wholesalers, helping support access to high-quality medical cannabis products for physicians and patients across Germany. With this foundation in Germany, Tilray Medical is helping define a more reliable, physician-led path for medical cannabis care.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama.

About Tilray Brands 

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships, including the Company’s collaboration with Molteni to support the development of the Italian medical cannabis market. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact:

Media: [email protected]  

Investors: [email protected]  

ATLANTA, Aug. 18, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:

ARS Pharmaceuticals, Inc. (SPRY)

The shareholder class action lawsuit filed against ARS Pharmaceuticals, Inc. (“ARS”) (NASDAQ: SPRY) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between March 9, 2026 and June 24, 2026 regarding ARS’s expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. If you purchased ARS shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/ars-pharmaceuticals/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 5, 2026.

Alarum Technologies Ltd. (ALAR)

The shareholder class action lawsuit filed against Alarum Technologies Ltd. (“Alarum”) (NASDAQ: ALAR) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between March 20, 2025 and July 2, 2026 regarding the impact of Alarum’s subsidiary, NetNut, on its legal exposure and business prospects. If you purchased Alarum shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/alarum-technologies/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 5, 2026. 

HDFC Bank Limited (HDB)

The shareholder class action lawsuit filed against HDFC Bank Limited (“HDFC”) (NYSE: HDB) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between July 17, 2023 and May 26, 2026 regarding HDFC’s practice of allegedly camouflaging payments as marketing spend to pay higher interest to a state firm in order to induce deposits. If you purchased HDFC shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/hdfc-bank/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 12, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

ATLANTA, Aug. 18, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:

Futu Holdings Limited (FUTU)

The shareholder class action lawsuit filed against Futu Holdings Limited (“Futu”) (NASDAQ: FUTU) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between May 24, 2023 and May 27, 2026 regarding Futu’s compliance with the requirements of the China Securities Regulatory Commission. If you purchased Futu shares and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/futu-holdings/ to learn more.   

The deadline to ask the court to be appointed lead plaintiff in the case is
August 25, 2026
.

Hub Group, Inc. (HUBG)

The shareholder class action lawsuit filed against Hub Group, Inc. (“Hub Group”) (NASDAQ: HUBG) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between April 28, 2023 and May 11, 2026 regarding Hub Group’s financial results, revenue recognition, and internal controls. If you purchased Hub Group shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at at www.holzerlaw.com/case/hub-group/ to learn more.    

The deadline to ask the court to be appointed lead plaintiff in the case is August 28, 2026. 

Insulet Corporation (PODD)

The shareholder class action lawsuit filed against Insulet Corporation (“Insulet”) (NASDAQ: PODD) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between February 21, 2025 and May 26, 2026 regarding Insulet’s manufacturing controls and procedures. If you purchased Insulet shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/insulet/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is August 31, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

ATLANTA, Aug. 18, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:

Hertz Global Holdings, Inc. (HTZ)

The shareholder class action lawsuit filed against Hertz Global Holdings, Inc. (“Hertz”) (NASDAQ: HTZ) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between May 7, 2026 and June 23, 2026 regarding Hertz’s liquidity. If you purchased Hertz shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/hertz-global-holdings/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is September 22, 2026. 

Wise Group plc (WSE)

The shareholder class action lawsuit filed against Wise Group plc (“Wise”) (NASDAQ: WSE) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between May 11, 2026 and July 23, 2026 regarding Wise’s understatement of alleged regulatory risks relating to deficient anti-money laundering efforts and insufficient efforts to prevent the financing of terrorism. If you purchased Wise shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/wise-group/ to learn more.    

The deadline to ask the court to be appointed lead plaintiff in the case is September 29, 2026. 

Pentair plc (PNR)

The shareholder class action lawsuit filed against Pentair plc (“Pentair”) (NYSE: PNR) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between March 11, 2025 and July 14, 2026 regarding significant destocking of inventory in Pentair’s Pool channel and its effect on sales and operating income. If you purchased Pentair shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/pentair/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 2, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI). BH-30643 is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial enrolling patients at more than 40 sites in 10 countries. ™

“Fast Track designation is an important regulatory milestone and reflects FDA’s recognition, based on its review of our preliminary data, of the potential for BH-30643 to address a significant unmet medical need in this molecularly defined population, for which no oral targeted therapies are approved,” said Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill Therapeutics. “Receiving this designation reaffirms our confidence in the development strategy for BH-30643 as a novel EGFR inhibitor designed to overcome C797S-mediated resistance. It also provides opportunities for more frequent engagement with FDA and potential access to other expedited programs, including potential eligibility for rolling review and accelerated approval, if applicable criteria are met.”

The FDA’s Fast Track process was designed to bring new medicines to patients more quickly, facilitating the development and expediting the review of therapies intended to treat serious conditions and address unmet medical needs. Companies whose programs are granted Fast Track designation are eligible for more frequent interactions with FDA regarding all aspects of a designated drug’s clinical development program, as well as for rolling review of a New Drug Application (NDA), meaning that completed sections may be submitted and reviewed on an ongoing basis rather than upon completion of the entire application. Fast Track–designated programs may also be eligible for Accelerated Approval and Priority Review if the applicable criteria for those programs are met. For more information on the Fast Track process, please visit the FDA’s official website.

About BH-30643

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain-active, mutant-selective, OMNI-EGFR inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical activating mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naïve settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical programs include BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of EGFR-mutant NSCLC with an initial development focus in the C797S resistance population after 3rd generation EGFR TKI treatment, and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS) and BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors. BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and differentiated profile of BH-30643; the anticipated benefits of Fast Track designation and whether the company will be able to meet the criteria to access other expedited programs; the design, enrollment, timing and results of the SOLARA trial; and other statements regarding management’s plans and expectations. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the risk that receipt of Fast Track designation may not result in a faster development, review or approval process compared to conventional FDA procedures, and does not increase the likelihood that BH-30643 will receive regulatory approval; the risk that the FDA may later determine that BH-30643 no longer meets the conditions for Fast Track designation, or may withdraw the designation; the risk that preliminary and interim clinical data, including data from the SOLARA trial, are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as the trial continues or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of BH-30643 and its other product candidates; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; competition, including from other agents in development for EGFR-mutant NSCLC; the company’s reliance on third parties; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s final prospectus dated August 6, 2026 and filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2026 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:

Michael Moore, BlossomHill Therapeutics
[email protected]

Media:

Ashlea Kosikowski, 1AB
[email protected]

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Virtu Financial (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, recently launched notional order execution capabilities for 10b-18 corporate buyback programs, a specialized offering available from only a small number of financial companies.

Virtu’s notional order functionality allows sell-side and buy-side clients to instruct execution based on a specified dollar (notional) value rather than a fixed share quantity, giving clients greater precision and control over corporate buyback spend. Notional trading values can be calculated with or without commission, offering clients added flexibility in how they define and manage total program spend.

Virtu supports 10b-18 instructions together with notional order execution across four algorithms: VWAP/TWAP, POV, FAN Aggressive and Passive, and Covert Aggressive — giving clients a range of strategies to align with their pacing, urgency, and risk preferences. This flexibility is valuable to corporate issuers and their broker-dealers executing repurchase programs, where precise budget management is as critical as execution quality.

“Notional orders represent a critical evolution in how corporate buybacks are executed, and we’re proud to be one of the few providers with the technology and expertise to build execution algorithms that give our clients precision, transparency, and confidence in managing these complex programs,” said Keith Casuccio, global head of sales, product and business development for Virtu Execution Services.

Truist Bank, one of Virtu’s key sell-side partners for 10b-18 notional order flow, recently shared internal performance metrics comparing Virtu’s notional order execution against a competing provider offering similar functionality. According to Truist’s analysis, Virtu’s execution outperformed the competitor on both benchmark performance and total notional value executed, underscoring the effectiveness of Virtu’s algorithmic approach to notional-based buyback programs.

“For corporate buyback programs, precision in managing notional spend is just as important as execution quality. Virtu’s notional order capability provides clients with greater flexibility to implement buyback strategies while maintaining a strong focus on execution quality,” said Nataliya Bershova, managing director, head of electronic equity trading, Truist Securities.

About Virtu Financial

Virtu is a leading provider of financial services and products that leverages cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to its clients. Leveraging its global market making expertise and infrastructure, Virtu provides a robust product suite including offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. Virtu’s product offerings allow clients to trade on hundreds of venues across 50+ countries and in multiple asset classes, including global equities, ETFs, foreign exchange, futures, fixed income, cryptocurrency and myriad other commodities. In addition, Virtu’s integrated, multi-asset analytics platform provides a range of pre-, intra-, and post-trade services, data products and compliance tools that clients rely upon to invest, trade and manage risk across global markets. Learn more at virtu.com.

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $556 billion as of June 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

Contact
Virtu Investor Relations
Matt Sandberg
[email protected]

Media
Petri Darby
[email protected]